Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
PURPOSE/OBJECTIVES: To comprehensively assess the patient and illness or treatment factors that may predict nonadherence to adjuvant endocrine therapy and to explore whether an interaction occurs between these factors in women with breast cancer. DESIGN: Repeated-measures design. SETTING: The Outpatient Services of the Women's Cancer Program at the University of Pittsburgh Cancer Institute and participants' homes. SAMPLE: 91 women with early-stage breast cancer who received endocrine therapy. METHODS: Adherence was assessed continuously for the first 18 months of endocrine therapy. Patient and illness or treatment factors were assessed at four time points (Time 1 to Time 4). Time 1 (baseline) was within two weeks prior to the initiation of endocrine therapy. Times 2-4 occurred at six-month intervals, as many as 18 months after Time 1. MAIN RESEARCH VARIABLES: Adherence, patient factors, and illness or treatment factors. FINDINGS: Adherence to endocrine therapy declined significantly during the first 18 months of treatment in women with breast cancer. The presence of negative mood and symptoms before starting treatment predicted nonadherence to endocrine therapy over time. Perceptions of financial hardship, symptoms, disease stage, and more complex medication regimens intensified the effect of negative mood on adherence over time. CONCLUSIONS: Women with breast cancer may be at risk for nonadherence to prescribed endocrine therapy if they experience depression or anxiety and symptoms prior to initiating therapy. IMPLICATIONS FOR NURSING: Oncology nurses should be alert to women with breast cancer who are depressed or anxious or who are experiencing symptoms. Management of negative mood and symptoms may result in better adherence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated anxiety predicts nonadherence to recommended therapies, [23][24][25] higher use and costs of medical care, [26][27][28] and possibly cancer recurrence.29”
From Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023) · cites this paper as [24]
Citations
Cites
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Horne, R., Weinman, J., & Hankins, M. (1999) · Psychology & Health · doi:10.1080/08870449908407311 · Cited by 2,372 · cited 1×
“Perceived treatment efficacy was evaluated with the 10-item Beliefs About Medicines Questionnaire (BMQ)–specific subscale (Horne, Weinman, & Hankins, 1999).”
Measuring the Functional Components of Social Support
Cohen, S., Mermelstein, R., Kamarck, T., & Hoberman, H. M. (1985) · Social Support: Theory, Research and Applications · doi:10.1007/978-94-009-5115-0_5 · Cited by 2,296 · cited 2×
“Test-retest correlations were 0.87 for two days, 0.7 for six weeks, and 0.74 for six months (Cohen et al., 1985).”
InfluentialSelf-citationPatient adherence to treatment: three decades of research. A comprehensive review
Vermeire, E., Hearnshaw, H., Van Royen, P., & Denekens, J. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00363.x · Cited by 1,833 · cited 1×
“Although the potential negative impact of financial hardship related to disease management on nonadherence has been explored (Griffith, 1990; Morris & Schulz, 1992; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), little is known about the role of financial hardship on”
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Mor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984) · Cancer · doi:10.1002/1097-0142(19840501)53:9<2002::aid-cncr2820530933>3.0.co;2-w · Cited by 1,067 · cited 1×
“Although the potential negative impact of financial hardship related to disease management on nonadherence has been explored (Griffith, 1990; Morris & Schulz, 1992; Vermeire, Hearnshaw, Van Royen, & Denekens, 2001), little is known about the role of financial hardship on”
Neuropsychological assessment.
Garb, H. N. (2004) · Studying the clinician: Judgment research and psychological assessment. · doi:10.1037/10299-006 · Cited by 876
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588 · cited 1×
“About 80% of breast cancers express hormone receptors (Konecny et al., 2003).”
Research works printed but not linked: 3
- D. McNair, 1992, EdITS manual for the profile of mood states
- H. Nelson, 1981, National adult reading test (NART) manual
- O. Spreen, 1998, A compendium of neuropsychogical test: Administration, norms, and commentary
Cited by
Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes
Smith, G. L., Lopez-Olivo, M. A., Advani, P. G., Ning, M. S., Geng, Y., Giordano, S. H., & Volk, R. J. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7305 · Cited by 437
A Systematic Review of Adherence to Oral Antineoplastic Therapies
Greer, J. A., Amoyal, N., Nisotel, L., Fishbein, J. N., MacDonald, J., Stagl, J., Lennes, I., Temel, J. S., Safren, S. A., & Pirl, W. F. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0405 · Cited by 344
Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
Andersen, B. L., Lacchetti, C., Ashing, K., Berek, J. S., Berman, B. S., Bolte, S., Dizon, D. S., Given, B., Nekhlyudov, L., Pirl, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00293 · Cited by 318
Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors
Bargon, C. A., Batenburg, M. C. T., van Stam, L. E., Mink van der Molen, D. R., van Dam, I. E., van der Leij, F., Baas, I. O., Ernst, M. F., Maarse, W., Vermulst, N., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa104 · Cited by 268
Mausbach, B. T., Schwab, R. B., & Irwin, S. A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3471-7 · Cited by 164
Lin, C., Clark, R., Tu, P., Bosworth, H. B., & Zullig, L. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4317-2 · Cited by 160
Treatment Satisfaction and Adherence to Oral Chemotherapy in Patients With Cancer
Jacobs, J. M., Pensak, N. A., Sporn, N. J., MacDonald, J. J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019729 · Cited by 169
Moon, Z., Moss-Morris, R., Hunter, M. S., Carlisle, S., & Hughes, L. D. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s126651 · Cited by 148
“Hot flushes/vasomotor symptoms, incontinence, gastrointestinal symptoms and sex-related symptoms were not associated with adherence, whereas weight concerns were associated with decreased odds of adherence.(40,41) Cognitive, gynecological, musculoskeletal and sleep/fatigue-related symptoms were associated with lower o…”
BackgroundDooley, L. N., Slavich, G. M., Moreno, P. I., & Bower, J. E. (2017) · Stress and Health · doi:10.1002/smi.2739 · Cited by 132
“Given that positive psychological adjustment to cancer has important implications for quality of life and can even influence medical adherence (Bender et al., 2014; Stanton et al., 2015), understanding the factors that contribute to resilience is of great importance.”
Lambert, L. K., Balneaves, L. G., Howard, A. F., & Gotay, C. C. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4561-5 · Cited by 142
“Specifically, non-adherence was significantly greater for women experiencing musculoskeletal pain [36, 38, 40, 49], headaches [45], nausea or visual complaints [50], gynecological symptoms [48, 50], menopausal symptoms [30, 46], cognitive symptoms [39, 48], weight concerns [38, 48, 53], fluid retention [30], poor slee…”
BackgroundPeddie, N., Agnew, S., Crawford, M., Dixon, D. L., Macpherson, I. R., & Fleming, L. (2021) · The Breast · doi:10.1016/j.breast.2021.05.005 · Cited by 137
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
“Fifteen studies [25,31,34,41,52,56,65,73,74,77,79,80,84,86,88] examined sociocultural factors (see Table 7).”
BackgroundGany, F. M., Melnic, I., Wu, M., Li, Y., Finik, J. M., Ramirez, J., Blinder, V. S., Kemeny, M., Guevara, E., Hwang, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02400 · Cited by 80
“Treatment adherence and completion affect cancer survival and QoL outcomes.(6-12)”
BackgroundFinitsis, D. J., Vose, B. A., Mahalak, J. G., & Salner, A. L. (2019) · Psycho-Oncology · doi:10.1002/pon.4959 · Cited by 68
Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
Lambert, L. K., Balneaves, L. G., Howard, A. F., Chia, S., & Gotay, C. C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4644-7 · Cited by 74
Camacho, F., Tan, X., Alcalá, H. E., Shah, S., Anderson, R. T., & Balkrishnan, R. (2017) · Medicine · doi:10.1097/md.0000000000007147 · Cited by 64
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach
Reinbolt, R. E., Mangini, N. S., Hill, J. L., Levine, L. B., Dempsey, J. L., Singaravelu, J., Koehler, K., Talley, A. W., & Lustberg, M. B. (2015) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2015.02.002 · Cited by 66
“The presence of negative mood prior to the initiation of therapy may also predict for non-adherence [34].”
Dyk, K. V., Crespi, C. M., Bower, J. E., Castellon, S. A., Petersen, L., & Ganz, P. A. (2018) · Cancer · doi:10.1002/cncr.31858 · Cited by 65
The 2014–2018 Oncology Nursing Society Research Agenda
Knobf, M., Cooley, M., Duffy, S., Doorenbos, A., Eaton, L., Given, B., Mayer, D., McCorkle, R., Miaskowski, C., Mitchell, S., et al. (2015) · Oncology Nursing Forum · doi:10.1188/15.onf.450-465 · Cited by 53
Self-citationMerriman, J. D., Sereika, S. M., Brufsky, A., McAuliffe, P. F., McGuire, K. P., Myers, J. S., Phillips, M. L., Ryan, C. M., Gentry, A., Jones, L. D., et al. (2015) · Psycho-Oncology · doi:10.1002/pon.4009 · Cited by 55
“Adherence to therapy may also improve [3].”
BackgroundSelf-citationBrier, M. J., Chambless, D. L., Gross, R., Chen, J., & Mao, J. J. (2017) · Cancer · doi:10.1002/cncr.30318 · Cited by 49
Fleming, L., Agnew, S., Peddie, N., Crawford, M., Dixon, D. L., & Macpherson, I. R. (2022) · The Breast · doi:10.1016/j.breast.2022.04.010 · Cited by 59
“Three good quality studies [21,52, 64] found a significant negative relationship, and 2 fair quality studies [69,77] found no significant relationship.”
InfluentialPolypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer
Calip, G. S., Xing, S., Jun, D.-H., Lee, W., Hoskins, K. F., & Ko, N. Y. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.018317 · Cited by 50
Irwin, M., & Johnson, L. A. (2015) · Clinical journal of oncology nursing · doi:10.1188/15.s1.cjon.6-30 · Cited by 44
Jacobs, J. M., Walsh, E. A., Park, E. R., Berger, J., Peppercorn, J. M., Partridge, A. H., Horick, N., Safren, S. A., Temel, J. S., & Greer, J. A. (2020) · International Journal of Behavioral Medicine · doi:10.1007/s12529-020-09908-2 · Cited by 44
“, depressive or anxiety symptoms) may be less likely to adhere to AET regimens [11].”
BackgroundGentry, A., Erickson, K. I., Sereika, S. M., Casillo, F. E., Crisafio, M. E., Donahue, P. T., Grove, G., Marsland, A. L., Watt, J. C., & Bender, C. M. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.02.012 · Cited by 43
“While the cognitive decline is typically mild or moderate, and does not meet clinical criteria for dementia, it can negatively impact survivors' ability to perform everyday tasks as well as long-term quality of life, occupational achievement, development and maintenance of social relationships, appropriate self-care a…”
Self-citationKrok-Schoen, J. L., Naughton, M. J., Young, G. S., Moon, J., Poi, M., Melin, S. A., Wood, M. E., Hopkins, J. O., Paskett, E. D., & Post, D. M. (2019) · Cancer Control · doi:10.1177/1073274819883287 · Cited by 37
Moon, Z., Moss-Morris, R. E., Hunter, M. S., & Hughes, L. D. (2017) · Psychology and Health · doi:10.1080/08870446.2016.1275629 · Cited by 44
Xu, H., Jin, F., Zhang, X., Wang, D., Yu, S., & Wang, A. (2020) · Cancer Medicine · doi:10.1002/cam4.3017 · Cited by 36
Londen, G. J. V., Donovan, H. S., Beckjord, E. B., Cardy, A., Bovbjerg, D. H., Davidson, N. E., Morse, J. Q., Switzer, G. E., Leeuw, I. M. V., & Dew, M. A. (2014) · Oncology nursing forum · doi:10.1188/14.onf.660-668 · Cited by 38
“Negative symptom experiences reported in the clinical literature appear to contribute to lack of adherence to AET (Bender et al., 2014; Cluze et al., 2011; Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004; Henry et al., 2012; Her-shman et al., 2010; Murphy, Bartholomew, Carpentier, Bluethmann,…”
Self-citationIbrar, M., Peddie, N., Agnew, S., Diserholt, A., & Fleming, L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.861198 · Cited by 37
“Also, the majority of studies in this area utilise quantitative, questionnaire-based methodologies to report this overall side effect profile, where presence/absence of side effects are reported as a single yes/no variable (Lash et al., 2006; Bender et al., 2014; Kyvernitakis et al., 2014).”
BackgroundUsing Information Technology in the Assessment and Monitoring of Geriatric Oncology Patients
Loh, K. P., McHugh, C. M., Mohile, S. G., Mustian, K. M., Flannery, M. A., Klepin, H. D., Schnall, R., Culakova, E., & Ramsdale, E. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0672-3 · Cited by 38
Smith, K. L., Verma, N., Blackford, A. L., Lehman, J., Westbrook, K. E., Lim, D., Fetting, J. H., Wolff, A. C., Jelovac, D., Miller, R. S., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00414-0 · Cited by 36
Beryl, L. L., Rendle, K. A. S., Halley, M. C., Gillespie, K. A., May, S. G., Glover, J., Yu, P. P., Chattopadhyay, R., & Frosch, D. L. (2016) · Medical Decision Making · doi:10.1177/0272989x16640488 · Cited by 30
Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer
Bender, C. M., Merriman, J. D., Sereika, S. M., Gentry, A., Casillo, F. E., Koleck, T. A., Rosenzweig, M. Q., Brufsky, A., McAuliffe, P. F., Zhu, Y., et al. (2018) · Oncology nursing forum · doi:10.1188/18.onf.308-326 · Cited by 35
Self-citationSystematic Review of Cognitive Impairment in Colorectal Cancer Survivors Who Received Chemotherapy
Chan, Y., Bryant, A. L., Conklin, J., Girdwood, T., Piepmeier, A. T., & Hirschey, R. (2021) · Oncology nursing forum · doi:10.1188/21.onf.634-647 · Cited by 31
“These deficits are problematic because they may affect individuals’ abilities to carry out daily activities, experience social connectedness (Selamat et al., 2014), adhere to treatment plans (Bender et al., 2014), and achieve a high quality of life (Lycke et al., 2019).”
BackgroundMcDonald, B. C., Dyk, K. V., Deardorff, R. L., Bailey, J. N., Zhai, W., Carroll, J., Root, J. C., Ahles, T. A., Mandelblatt, J. S., & Saykin, A. J. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06597-1 · Cited by 26
Gil-Guillén, V. F., Balsa, A., Bernárdez, B., y Llorca, C. V., Contreras, E. M., de la Haba-Rodríguez, J., Castellano, J. M., & Martínez, J. C. G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912036 · Cited by 39
“symptoms’, consequently having a negative impact on non-adherence [56,60,70,78,100,106].”
BackgroundMarkovitz, L. C., Drysdale, N. J., & Bettencourt, B. A. (2016) · Psycho-Oncology · doi:10.1002/pon.4362 · Cited by 33
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
Mian, H. S., Fiala, M. A., & Wildes, T. M. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.618 · Cited by 28
Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama
Guedes, J. B. R., Guerra, M. R., Alvim, M. M., & Leite, I. C. G. (2017) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-5497201700040007 · Cited by 45
“A presença e a gravidade dos sintomas da doença são fatores capazes de interferir no seguimento do tratamento 35 .”
Tumour brain: Pretreatment cognitive and affective disorders caused by peripheral cancers
Mampay, M., Flint, M. S., & Sheridan, G. K. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15571 · Cited by 32
“bances often decrease the quality of life of people diagnosed with cancer, and this can have knock-on effects, such as reducing patient adherence to chemotherapy drug regimens and decreasing overall survival rates (Bender et al., 2014; Janelsins et al., 2014).”
BackgroundFactors Associated With Medication Beliefs in Patients With Cancer: An Integrative Review
Marshall, V. K., & Given, B. A. (2018) · Oncology nursing forum · doi:10.1188/18.onf.508-526 · Cited by 26
“…and side effects may be used to weigh whether patients adhere to cancer treatment because they may believe their symptoms outweigh the benefit of taking medication (Bender et al., 2014; Bhattacharya, Easthall, Willoughby, Small, & Watson, 2012; Gatti et al., 2009; Iskandarsyah et al., 2014).”
Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors
Brier, M. J., Chambless, D. L., Chen, J., & Mao, J. J. J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.12.006 · Cited by 27
Impact of anxio-depressive symptoms and cognitive function on oral anticancer therapies adherence
Santos, M. D., Lange, M., Gervais, R., Clarisse, B., Capel, A., Barillet, M., Grellard, J., Heutte, N., Licaj, I., & Joly, F. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-4644-4 · Cited by 27
Iacorossi, L., Gambalunga, F., Fabi, A., Giannarelli, D., Marchetti, A., Piredda, M., & Marinis, M. G. D. (2016) · Cancer Nursing · doi:10.1097/ncc.0000000000000452 · Cited by 31
“Negative beliefs regarding the value of endocrine therapy are likely to cause more interruptions in therapy and are associated with an increased risk of nonadherence.(12) The literature also shows a clear understanding of the relationship between clinical outcome and medication adherence as a key factor in getting pat…”
BackgroundYanez, B. R., Gray, R. J., Sparano, J. A., Carlos, R. C., Sadigh, G., Garcia, S. F., Gareen, I. F., Whelan, T. J., Sledge, G. W., Cella, D. F., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1693 · Cited by 25
Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers
Vaz-Luís, I., Francis, P. A., Meglio, A. D., & Stearns, V. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320595 · Cited by 25
Park, S. K., Min, Y. H., & Lee, S. B. (2021) · Healthcare · doi:10.3390/healthcare9091223 · Cited by 21
“Evidence shows that depression in patients with breast cancer increases poor adherence to cancer treatment [8,9], cancer recurrence [10,11], and cancer-specific mortality [10].”
Background“Winging It”: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment
Brauer, E. R., Ganz, P. A., & Pieters, H. C. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011767 · Cited by 21
“Limited evidence suggests early discontinuation of hormonal treatments is associated with older age(11,12) and adverse effects(13,14) and usually occurs within the first year, but may also occur in subsequent years.(15,16) However, underlying reasons for these decisions remain poorly understood.”
BackgroundXu, H., Zhang, X., Wang, D., Xu, L., & Wang, A. (2019) · Journal of Advanced Nursing · doi:10.1111/jan.14253 · Cited by 23
Mao, D., Hachem, H., Chang, H., Dima, D., Dower, J., Wismer, M., Erban, J. K., Freund, K. M., & Parsons, S. K. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05892-z · Cited by 20
Gallups, S., Connolly, M. C., Bender, C. M., & Rosenzweig, M. Q. (2018) · Women s Health Issues · doi:10.1016/j.whi.2018.08.001 · Cited by 19
Self-citationMeglio, A. D., Soldato, D., Presti, D., & Vaz-Luís, I. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000781 · Cited by 22
Ream, M. E., Walsh, E. A., Jacobs, J. M., Taub, C. J., Lippman, M. E., Solle, N. S., Safren, S. A., & Antoni, M. H. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06361-x · Cited by 21
“This may be an explanation for inconsistent results in the literature linking anxiety to adherence [8, 29, 48].”
BackgroundResultPinheiro, L. C., Wheeler, S. B., Reeder-Hayes, K. E., Samuel, C. A., Olshan, A. F., & Reeve, B. B. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.018630 · Cited by 19
Novel approaches to support breast cancer survivorship care models
Gast, K. C., Allen, S. V., Ruddy, K. J., & Haddad, T. C. (2017) · The Breast · doi:10.1016/j.breast.2017.08.004 · Cited by 21
Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
Lee, J. Y., & Min, Y. H. (2018) · BMC Women s Health · doi:10.1186/s12905-018-0522-3 · Cited by 23
Quinn, E. M., Fleming, C., & O’Sullivan, M. J. (2015) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-015-1307-4 · Cited by 21
Jacobs, J. M., Walsh, E. A., Rapoport, C. S., Antoni, M. H., Park, E. R., Post, K. E., Comander, A. H., Peppercorn, J. M., Safren, S. A., Temel, J. S., et al. (2020) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-020-09750-4 · Cited by 18
Smith, K. L., Tsai, H., Lim, D., Wang, C., Nunes, R., Wilkinson, M. J., Sheng, J. Y.-S., Couzi, R. J., Fetting, J. H., Riley, C. D., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00038 · Cited by 15
Yang, S., Park, S. W., Bae, S. J., Ahn, S. G., Jeong, J., & Park, K. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e22 · Cited by 20
“A family history of breast or ovarian cancer [80,100], frailty [61], pain [42,46,101,102], poor sleep quality [103,104], smoking/substance use [54,66,85,105,106], lower cognitive function [48,55,61,67,90,94,107], concern belief [32,46,105,108-110], strong belief in the risk of recurrence [47], negative decisional bala…”
BackgroundTyrosine kinase inhibitors in cancers: Treatment optimization – Part II
Ferrer, F., Tétu, P., Dousset, L., Lebbé, C., Ciccolini, J., Combarel, D., Meyer, N., Paci, A., & Bouchet, S. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104385 · Cited by 16
Wagner, M. A., Erickson, K. I., Bender, C. M., & Conley, Y. P. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00123 · Cited by 17
Self-citationKaravites, L. C., Allu, S., Khan, S. A., & Kaiser, K. (2015) · BMC Cancer · doi:10.1186/s12885-015-1893-6 · Cited by 15
“Low perceived financial status which has been shown to apply to populations with both high and low incomes [8, 27, 28].”
BackgroundTreatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer
Wassermann, J., & Rosenberg, S. M. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0248-5 · Cited by 14
Problem-solving skills training in adult cancer survivors: Bright IDEAS-AC pilot study
Noyes, K., Zapf, A., Depner, R. M., Flores, T. F., Huston, A. J., Rashid, H. H., McNeal, D. M., Constine, L. S., Fleming, F. J., Wilding, G. E., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100552 · Cited by 16
Alchin, J. E., Signorelli, C., McLoone, J. K., Wakefield, C. E., Fardell, J. E., Johnston, K. A., & Cohn, R. J. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s363653 · Cited by 15
Hertz, D. L., Smith, K. L., Zong, Y., Gersch, C. L., Pesch, A. M., Lehman, J., Blackford, A. L., Henry, N. L., Kidwell, K., Rae, J. M., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.662734 · Cited by 14
“Determinants of AI non-adherence and early discontinuation are multifactorial and include both baseline and treatment-emergent symptoms, especially AI-induced musculoskeletal symptoms (AIMSS) (Partridge et al., 2003, 2008; Felson and Cummings, 2005; Henry et al., 2012; Murphy et al., 2012; Chim et al., 2013; Bender et…”
BackgroundDepression and Anxiety - Risk Factors in the Evolution of Breast Cancer in Women
Schenker, R. A., Ciurea, M. E., Stovicek, P. O., Ciubară, A., Schenker, M., & Marinescu, I. P. (2022) · BRAIN BROAD RESEARCH IN ARTIFICIAL INTELLIGENCE AND NEUROSCIENCE · doi:10.18662/brain/13.1sup1/309 · Cited by 14
Lima, M. T. M., de Carvalho, K. P., Mazzutti, F. S., Maia, M. D. A., Canto, P. P. L., Paiva, C. E., & Maia, Y. C. D. P. (2017) · BMC Cancer · doi:10.1186/s12885-017-3559-z · Cited by 12
Mohammed, S. I., Sabry, A. T., & Sabry, D. T. (2021) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol30iss2pp113-121 · Cited by 11
“However, poor adherence can be attributed to long treatment duration and lifestyle changes such as sleeping routines, social status, or mealtime ((17,18)).”
BackgroundSymptoms and QOL in breast cancer patients receiving hormone therapy in Japan
Iioka, Y., Iwata, T., & Yamauchi, H. (2019) · Breast Cancer · doi:10.1007/s12282-019-00993-0 · Cited by 11
Peled, O., Lavan, O., Stein, J., Vinograd, I., Yahel, A., Valevski, A., Weizman, A., Kimmel-Tamir, E., Apter, A. S., Fennig, S., et al. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0164 · Cited by 11
Yin, Z., Xie, W., & Malin, B. (2017) · PubMed Central · Cited by 10
Yanez, B. R., Oswald, L. B., Denburg, A. N. V., Baik, S. H., Czech, K. A., Buitrago, D., Maletich, C., Wortman, K., Penedo, F. J., & Victorson, D. E. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100898 · Cited by 10
Grapp, M., Bugaj, T. J., Terhoeven, V., Friederich, H., & Maatouk, I. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316853 · Cited by 13
Ucciero, S., Lacarbonara, F., Durante, Á., Torino, F., Uchmanowicz, I., Vellone, E., & Nitto, M. D. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307838 · Cited by 10
Samuel, C. A., Turner, K. L., Donovan, H. S., Beckjord, E. B., Cardy, A., Dew, M. A., & Londen, G. J. V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3799-0 · Cited by 10
Self-citationLiou, K. T., McConnell, K. M., Currier, M. B., Baser, R. E., MacLeod, J., Walker, D. A. H., Casaw, C., Wong, G., Piulson, L., Popkin, K., et al. (2023) · JMIR Research Protocols · doi:10.2196/46281 · Cited by 12
“Anxiety also contributes to poor treatment adherence [18-20] and increased health care expenditures [21,22].”
Cognitive Function in Adults With Acute Myeloid Leukemia Treated With Chemotherapy
Chan, Y., Betancur, S., Conklin, J., Hirschey, R., Piepmeier, A. T., Foster, M., Anderson, R. A., Bender, C. M., & Bryant, A. L. (2022) · Cancer Nursing · doi:10.1097/ncc.0000000000001164 · Cited by 8
Self-citationTrevino, K. M., Iyengar, N. M., Li, Q., & Mao, J. J. J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05859-0 · Cited by 11
Saad, A. H., Rabeea, I. S., & Salih, H. (2022) · Iraqi Journal of Pharmaceutical Sciences · doi:10.31351/vol30isssuppl.pp31-39 · Cited by 15
Amlani, A., Kumar, A., Ruan, J. Y., & Cheung, W. Y. (2016) · Cancer Medicine · doi:10.1002/cam4.745 · Cited by 10
Marshall, V. K., Lehto, R. H., Given, C. W., Given, B. A., & Sikorskii, A. E. (2019) · European Journal of Cancer Care · doi:10.1111/ecc.12988 · Cited by 12
Psychometric Properties of the Self Care Oral Anticancer Agents Index (SCOAAI)
Nitto, M. D., Ucciero, S., Bolgeo, T., Damico, V., Ghizzardi, G., Zerulo, S. R., Roselli, M., Alvaro, R., Torino, F., & Vellone, E. (2025) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2025.151810 · Cited by 7
Development of health behaviour questionnaire for breast cancer women in Mainland China
Xu, H., Jiang, G., Zhang, X., Wang, D., Xu, L., & Wang, A. (2020) · Nursing Open · doi:10.1002/nop2.737 · Cited by 5
“AET reduces recurrence and mortality in BrCa women significantly (Anderson et al., 2014; Bender et al., 2014; Harrow et al., 2014; Weaver et al., 2013).”
BackgroundDibble, K. E., Baumgartner, R., Boone, S. D., Baumgartner, K. B., & Connor, A. E. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06900-8 · Cited by 7
“, pain, gynecologic and cognitive symptoms) negatively impact adherence to tamoxifen [51, 57].”
BackgroundAngst und Emotionsregulation bei Krebspatienten
Bussmann, S., Vaganian, L., Kusch, M., Labouvie, H., Gerlach, A. L., & Cwik, J. C. (2018) · Psychotherapeut · doi:10.1007/s00278-018-0283-3 · Cited by 9
Saxby, K., Nickson, C., Mann, G. B., Park, A., Bromley, H. L., Velentzis, L. S., Procopio, P., Canfell, K., & Petrie, D. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1857735 · Cited by 6
Correlates of Adjuvant Therapy Attitudes in African American Breast Cancer Patients
Edmonds, M. C., Sutton, A. L., He, J., Perera, R. A., & Sheppard, V. B. (2020) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.02.006 · Cited by 6
Marshall, V. K., Given, C. W., Sikorskii, A. E., Given, B. A., & Lehto, R. H. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-05073-9 · Cited by 5
Marano, G., Paris, I., Traversi, G., Mazza, O., Pavese, F., D’Angelo, T., Franceschini, G., & Mazza, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041574 · Cited by 5
“Maladaptive coping strategies, such as avoidance, denial, catastrophizing, and emotional suppression, correlate with elevated distress, decreased adherence, and poorer quality of life [12,16].”
Nugent, B. D., Sereika, S. M., Rosenzweig, M. Q., McCue, M. P., Merriman, J. D., & Bender, C. M. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3161-y · Cited by 4
“This knowledge is important because other studies have found that severity of symptoms predict poor adherence to treatment [27, 28] and who will remain employed [12, 24, 29].”
Self-citationHaskins, C., Neuner, J. M., McDowell, B. D., Carnahan, R. M., Fiedorowicz, J. G., Wallace, R. B., Smith, B. J., & Chrischilles, E. A. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.09.005 · Cited by 4
“Negative mood effects were amplified when combined with disease stage and symptoms, financial concerns, and complex medication regimens [17].”
Shi, L., Zhang, J., & Deng, Y. (2025) · BMC Medicine · doi:10.1186/s12916-025-04128-5 · Cited by 4
“To better understand the association between emotion and treatment adherence among patients with locally advanced rectal cancer, factors that might be associated with treatment adherence were also included in the analysis as covariates [16, 21–23].”
Walsh, E. A., Walsh, L. E., Hernand, M. G., Horick, N., Antoni, M. H., Temel, J. S., Greer, J. A., & Jacobs, J. M. (2024) · Journal of Cancer Survivorship · doi:10.1007/s11764-024-01556-9 · Cited by 3
“Other research suggests that women with low mood prior to initiating AET are likely to be non-adherent to their medication [15, 16], particularly young women [17].”
Rivers, A. S., Sanford, K., Elkins, G. R., Carpenter, J. S., Rand, K. L., & Ellis, R. J. B. (2020) · Journal of Health Psychology · doi:10.1177/1359105320982039 · Cited by 3
“For example, many studies examining OET adherence have found null effects of psychosocial variables similar to those included in the model (Bender et al., 2014; Bright and Stanton, 2018; Moon et al., 2017; Stanton et al., 2014), including adherence attitudes or beliefs (Bender et al., 2014; Brier…”
BackgroundResultPerrier, J., Joue, G., Desgranges, B., Allouache, D., Lévy, C., Noal, S., Dayan, J., Eustache, F., Joly, F., Viard, A., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15587 · Cited by 3
“These changes negatively impact quality of life (Lange & Joly, 2017) and adherence to treatments (Bender et al., 2014), making the need to address these issues in BC patient support care through cognitive and psychological interventions crucial (Lange & Joly, 2017).”
BackgroundPodsada, M. K., Ryan, J. C., & Orbaugh, K. (2020) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2020.11.7.5 · Cited by 2
“Because adherence to oral oncology medications is variable at best—in some studies, nearly half of the patients reported some level of nonadherence (Bender et al., 2014; Thomas et al., 2019)—establishing a rapport and proactively addressing potential barriers to adherence is crucial to an effective…”
BackgroundInfluential
Metadata
- Authors
- Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., Sherwood, P. R., & Sereika, S. M.
- Affiliations
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh (US)
- ORCID
- Venue
- Oncology Nursing Forum
- Publisher
- Oncology Nursing Society (ONS)
- Published
- 2014-04-25
- Volume
- 41
- Issue
- 3
- Pages
- 274-285
- ISSN
- 0190-535X (ISSN-L)
- 1538-0688
- PMC
- PMC4090095
- OpenAlex
- W1992203573
- Cited by
- 131
- References
- 50
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 17 · 2019: 11 · 2018: 12 · 2017: 15 · 2016: 8 · 2015: 8 · 2014: 1
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncology nursing forum (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Cancer Institute (R01CA107408)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- breast cancer, adjuvant endocrine therapy, medication adherence, non-compliance, negative mood, depression, anxiety, financial hardship, symptom burden, disease stage, medication regimen complexity, predictors of non-adherence
- MeSH terms
- Adolescent, Adult, Affect, Aged, Breast Neoplasms, Depression, Female, Follow-Up Studies, Forecasting, Humans, Middle Aged, Patient Compliance, Pennsylvania, Socioeconomic Factors, Tamoxifen, Time Factors, Comorbidity, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.